Clofarabine

• CAT Number: A001053
• CAS Number: 123318-82-1
• Molecular Formula: C10H11ClFN5O3
• Molecular Weight: 303.7
• Purity: ≥95%
• Target: DNA Synthesis
• Solubility: >15.2mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
• InChIKey: WDDPHFBMKLOVOX-AYQXTPAHSA-N
• SMILES: C1=NC2=C(N1C3C(C(C(O3)CO)O)F)N=C(N=C2N)Cl

Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5/’-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factor, which activate apoptosis.

Reference

1: Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL,
Talpaz M, Perissinotti AJ. Outcomes of previously untreated elderly patients with
AML: a propensity score-matched comparison of clofarabine vs. FLAG. Ann Hematol.
2017 Dec 29. doi: 10.1007/s00277-017-3217-1. [Epub ahead of print] PubMed PMID:
29288428.

2: Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B,
Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL,
Hunger SP. Toxicity associated with intensive postinduction therapy incorporating
clofarabine in the very high-risk stratum of patients with newly diagnosed
high-risk B-lymphoblastic leukemia: A report from the Children/’s Oncology Group
study AALL1131. Cancer. 2017 Dec 19. doi: 10.1002/cncr.31099. [Epub ahead of
print] PubMed PMID: 29266189.

3: Muluneh B, Buhlinger K, Deal AM, Zeidner JF, Foster MC, Jamieson KJ, Bates J,
Van Deventer HW. A Comparison of Clofarabine-based (GCLAC) and Cladribine-based
(CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. Clin Lymphoma Myeloma
Leuk. 2018 Jan;18(1):e13-e18. doi: 10.1016/j.clml.2017.09.016. Epub 2017 Sep 22.
PubMed PMID: 29100976.

4: Messinger Y, Boklan J, Goldberg J, DuBois SG, Oesterheld J, Abla O, Martin A,
Weinstein J, Hijiya N. Combination of clofarabine, cyclophosphamide, and
etoposide for relapsed or refractory childhood and adolescent acute myeloid
leukemia. Pediatr Hematol Oncol. 2017 May;34(4):187-198. doi:
10.1080/08880018.2017.1360970. Epub 2017 Oct 17. PubMed PMID: 29039989.

5: Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett
W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M,
Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O/’Brien SM, Cortes JE,
Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to
idarubicin and cytarabine for adults with relapsed or refractory acute myeloid
leukemia. Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349907.
[Epub ahead of print] PubMed PMID: 28718728.

6: Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W,
Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M,
Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O/’Brien SM, Cortes JE,
Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with
clofarabine or fludarabine in patients with newly diagnosed acute myeloid
leukemia. Cancer. 2017 Nov 15;123(22):4430-4439. doi: 10.1002/cncr.30883. Epub
2017 Jul 14. PubMed PMID: 28708931; PubMed Central PMCID: PMC5739034.

7: Benitez LL, Gharibian K, Frame D, Mody R, Mora E. Clofarabine Dosing in a
Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and
Review of the Literature. J Pediatr Hematol Oncol. 2017 Aug;39(6):481-484. doi:
10.1097/MPH.0000000000000845. PubMed PMID: 28538504.

8: Büttner B, Knoth H, Kramer M, Oertel R, Seeling A, Sockel K, von Bonin M,
Stölzel F, Alakel N, Platzbecker U, Röllig C, Ehninger G, Bornhäuser M, Schetelig
J, Middeke JM. Impact of pharmacokinetics on the toxicity and efficacy of
clofarabine in patients with relapsed or refractory acute myeloid leukemia. Leuk
Lymphoma. 2017 Dec;58(12):2865-2874. doi: 10.1080/10428194.2017.1319051. Epub
2017 May 16. PubMed PMID: 28509593.

9: Jain P, Klotz J, Dunavin N, Lu K, Koklanaris E, Draper D, Superata J, Chinian
F, Yu Q, Keyvanfar K, Wong S, Muranski P, Barrett AJ, Ito S, Battiwalla M.
Cellular immune profiling after sequential clofarabine and lenalidomide for high
risk myelodysplastic syndromes and acute myeloid leukemia. Leuk Res Rep. 2017 Apr
13;7:40-44. doi: 10.1016/j.lrr.2017.04.003. eCollection 2017. PubMed PMID:
28462085; PubMed Central PMCID: PMC5402630.

10: Punt AM, Langenhorst JB, Egas AC, Boelens JJ, van Kesteren C, van Maarseveen
EM. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using
isotope labelled standards and standard addition in plasma by LC-MS/MS for
exposure monitoring in hematopoietic cell transplantation conditioning. J
Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jun 15;1055-1056:81-85. doi:
10.1016/j.jchromb.2017.04.025. Epub 2017 Apr 15. PubMed PMID: 28445850.